PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
35230716-7	2022	Using tofacitinib, a clinical JAK inhibitor, the study showed that SM deficiency might participate in STAT3 phosphorylation via JAK activation.	tofacitinib	6-17	signal transducer and activator of transcription 3	Mus musculus	102-107	
22252297-8	2012	CP-690,550 selectively inhibited IFN--induced STAT1, IL-4-induced STAT6 and IL-2-induced STAT5 at 3-30nM, while suppression of IL-6-induced STAT3 phosphorylation required a concentration greater than 100nM.	tofacitinib	0-6	signal transducer and activator of transcription 3	Mus musculus	140-145	
34547509-7	2021	ERK and JAK-STAT signaling were blocked using the inhibitors U0126 and Tofacitinib, respectively.	tofacitinib	71-82	signal transducer and activator of transcription 3	Mus musculus	12-16	
34626614-6	2022	Finally, treatment of mice with the pan-Jak inhibitor, tofacitinib, reduced psoriasis-like dermatitis and epidermal STAT3 phosphorylation.	tofacitinib	55-66	signal transducer and activator of transcription 3	Mus musculus	116-121	
33511217-0	2021	Tofacitinib Ameliorates Lipopolysaccharide-Induced Acute Kidney Injury by Blocking the JAK-STAT1/STAT3 Signaling Pathway.	tofacitinib	0-11	signal transducer and activator of transcription 3	Mus musculus	97-102	
33511217-8	2021	These results may be associated with the inhibitory effect of TOFA on the JAK-STAT1/STAT3 pathway, which was significantly activated by LPS challenge.	tofacitinib	62-66	signal transducer and activator of transcription 3	Mus musculus	84-89